Anti-inflammatory Mechanism of Ruzu Bitters on Diet-Induced Nonalcoholic Fatty Liver Disease in Male Wistar Rats

Table 3

The trend in body weight (grams) changes during the treatment period of 12 weeks.

Groups	Normal	PIO	RUZU	NAFLD	FENO
Start	170.00 ± 8.94	186.80 ± 7.50	180.80 ± 7.96	182.80 ± 9.34	196.00 ± 11.24
Week 2	182.60 ± 10.34	200.00 ± 6.54	195.60 ± 10.83	200.60 ± 5.02	205.20 ± 12.66
Week 4	196.80 ± 9.65	212.80 ± 9.65	206.40 ± 11.03	221.00 ± 5.60	214.40 ± 13.61
Week 6	205.20 ± 10.29^b	222.00 ± 7.85^b	218.00 ± 10.90^b	256.20 ± 5.68^a	226.00 ± 14.18^b
Week 8	218.80 ± 10.59^b	236.80 ± 6.86^b	229.20 ± 11.77^b	288.60 ± 6.19^a	239.20 ± 15.60^b
Week 10	231.20 ± 10.76^b	251.60 ± 5.88^b	238.80 ± 12.09^b	310.80 ± 6.17^a	250.80 ± 16.55^b
Week 12	234.20 ± 9.47^b	259.60 ± 4.78^b	253.40 ± 14.65^b	332.40 ± 7.23^a	257.00 ± 15.82^b

Values are presented as mean ± SEM (n = 5). , a significant difference compared to the normal control. , a significant difference compared to the NAFLD group. NAFLD: nonalcoholic fatty liver disease, PIO: pioglitazone (4 mg/kg body weight), RUZU: Ruzu herbal bitters (0.6 mg/kg body weight), and FENO: fenofibrate (10 mg/kg body weight).